32 results on '"Wiebringhaus H"'
Search Results
2. Papierlose Patienten- und Studiendokumentation beim Mammakarzinom — ein wesentlicher Beitrag zur Messung der Ergebnissqualität in Zentren
3. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
4. Disease-Management-Programm (DMP) Brustkrebs in Nordrhein: Eine Chance für eine zusätzliche Qualitäts- sicherung durch ein add on: S184
5. Erste Erfahrungen mit der elektronischen Dokumentation in NRW und dem Aufbau eines Benchmarking in über 30 Schwerpunktkliniken für Brustkrebs: S185
6. Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer-GBG69
7. Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)
8. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer : a subanalysis of data from the randomized phase III GeparSepto trial
9. Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)
10. Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69
11. nab-paclitaxel at a dose of 125 mg/m(2) weekly is more efficacious but less toxic than at 150 mg/m(2) : Results from the neoadjuvant randomized GeparSepto study (GBG 69)
12. Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial
13. Abstract P5-16-03: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)
14. 188PD - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)
15. Drei Fälle eines Riesenzellfibroms des Stimmbandes
16. Benchmarking als Qualitätssicherungsmassnahme in der Senologie und die Entwicklung von 2003 bis 2006 in Deutschland/NRW
17. Weekly Dose-Dense Treatment with Taxanes in Metastatic Breast Cancer
18. La recepción del recurso contenciosoadministrativo en la Comunidad Europea del Carbón y del Acero J. Antonio Carrillo Salcedo
19. Il Fenomeno dell'Organizzazione e la Comunità Internazionale Alessandro Migliazza
20. Diritto Internazionale, II, 2 (Soggetti a carattere funzionale — Le Organizzazione Internazionali) Angelo Piero Sereni
21. Kernenergierecht, Heft 1 (Grossbritannien)
22. Derecho Internacional Privado, Bd. I (Allg. Teil) Mariano Aguilar Navarro
23. European Assemblies. The Experimental Period 1949-1959 Kenneth Lindsay
24. Diritto Internazionale (Bd. I, 1956, Bd. II: Organizzazione internazionale, Sezione Prima: « Soggetti a carattere territoriale », 1958 Angelo Piero Sereni
25. The European Social Charter, by David J. Harris. University Press of Virginia, Charlottesville, 1984, xviii + 345 pp. $35
26. Die Philosophie des Rechts in historischer Perspektive
27. Die Rom-Konvention fur Menschenrechte in der Praxis der Strassburger Menschenrechtskommission
28. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
29. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
30. Efficacy and safety of nab-paclitaxel 125 mg/m 2 and nab-paclitaxel 150 mg/m 2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
31. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
32. [Three cases of giant cell fibroma of the vocal cord (author's transl)].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.